Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Capital Expenditures: 2010-2025

Historic Capital Expenditures for OptimizeRx (OPRX) over the last 15 years, with Q2 2025 value amounting to $34000.0.

  • OptimizeRx's Capital Expenditures fell 1500.0% to $34000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $148000.0, marking a year-over-year decrease of 5842.7%. This contributed to the annual value of $338000.0 for FY2024, which is 5688.78% down from last year.
  • OptimizeRx's Capital Expenditures amounted to $34000.0 in Q2 2025, which was down 1500.0% from $57000.0 recorded in Q1 2025.
  • OptimizeRx's Capital Expenditures' 5-year high stood at $1.5 million during Q3 2023, with a 5-year trough of -$777000.0 in Q4 2023.
  • Moreover, its 5-year median value for Capital Expenditures was $31500.0 (2023), whereas its average is $96707.0.
  • Over the last 5 years, OptimizeRx's Capital Expenditures had its largest YoY gain of 638037.03% in 2023, and its largest YoY loss of 88569.77% in 2023.
  • Over the past 5 years, OptimizeRx's Capital Expenditures (Quarter) stood at $301601.0 in 2021, then tumbled by 67.21% to $98893.0 in 2022, then plummeted by 885.7% to -$777000.0 in 2023, then skyrocketed by 113.26% to $103000.0 in 2024, then plummeted by 66.99% to $34000.0 in 2025.
  • Its last three reported values are $34000.0 in Q2 2025, $57000.0 for Q1 2025, and $103000.0 during Q4 2024.